Table 3. Description of CRC cases by study.
| Study (N) | APPS (837) | CPPS (913) | AFT (1086) | PPT (2024) | WBF (1304) | NPS (939) | VA (871) | UDCA (1193) | Total |
|---|---|---|---|---|---|---|---|---|---|
| CRC, N (%/N study) | 5 (0.6) | 8 (0.9) | 6 (0.6) | 13 (0.6) | 8 (0.6) | 3 (0.3)* | 8 (0.9) | 7 (0.6) | 58 (0.6) |
| Cancer/1000 person-years follow-up | 1.52 | 2.24 | 1.77 | 1.52 | 1.77 | 1.14* | 2.14 | 1.69 | 1.71 |
| Stage I or II CRC N | 5 | 6 | 5 | 8 | 8 | 3 | 5 | 5 | 45 |
| Right sided N (%) | 2 | 4 | 4 | 5 | 5 | 3 | 5 | 1 | 29 |
| Died CRC N (%) | 0 | 2 | 0 | 2 | 2 | 0 | 3 | 0 | 9 |
*
Does not include two cancers detected after the first 3 years of this study during a longer period of clinical follow-up as reported elsewhere.15
AFT, Aspirin Folate Trial; APPS, Antioxidant Polyp Prevention Study; CPPS, Calcium Polyp Prevention Study; CRC, colorectal cancer; NPS, National Polyp Study; PPT, Polyp Prevention Trial; UDCA, Ursodoxycholic Acid Study; VA, Veterans Affairs Cooperative Study; WBF, Wheat Bran Fiber Study.